Janux Therapeutics, Inc. (JANX) Earnings History

Janux Therapeutics, Inc. - Q4 FY2025 Earnings

Filed at: Feb 26, 2026, 4:10 PM EST|Read from source

EXECUTIVE SUMMARY

Janux Therapeutics reported significant clinical and strategic progress in Q4 2025, highlighted by updated Phase 1 data for JANX007 and a key collaboration with Bristol Myers Squibb. The company strengthened its leadership team and ended the year with a robust cash position to support pipeline advancement.

POSITIVE HIGHLIGHTS

  • •

    Updated interim Phase 1 data for JANX007 showed durable clinical activity with median rPFS ranging from 7.9 to 8.9 months and deep PSA declines.

    positive
  • •

    Entered into a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic.

    positive
  • •

    Janux is eligible to receive $50 million in upfront and near-term milestone payments from the Bristol Myers Squibb collaboration, with potential for additional milestones totaling approximately $800 million.

    positive
  • •

    Appointment of William Go, M.D., Ph.D., as Chief Medical Officer strengthens clinical leadership.

    positive

CONCERNS & RISKS

  • •

    Net loss for the quarter was $42.4 million, an increase from $20.2 million in Q4 2024.

    negative
  • •

    Research and development expenses increased to $31.5 million for the quarter, up from $20.8 million in Q4 2024.

    attention
  • •

    General and administrative expenses increased to $10.9 million for the quarter, up from $8.2 million in Q4 2024.

    attention
  • •

    Net loss per common share was $(0.51) for the quarter, compared to $(0.36) in Q4 2024.

    negative

FINANCIAL METRICS

Revenue
Quarterly
$0.00
N/A
Prior year: $0.00
Annual (YTD)
$10.00K
N/A
Prior year: $10.59K
Net Income
Quarterly
$-42.40M
-109.8%
Prior year: $-20.22M
Annual (YTD)
$-157.67M
N/A
Prior year: $-68.99M
EPS (Diluted)
Quarterly
$-0.51
-41.7%
Prior year: $-0.36
Operating Income
Quarterly
$-42.40M
-46.1%
Prior year: $-29.02M
Annual (YTD)
$-157.67M
N/A
Prior year: $-98.85M
EPS (Basic)
Quarterly
$-0.51
-41.7%
Prior year: $-0.36

MARGIN ANALYSIS

Operating Margin
Current Quarter
-42401.0%
Prior Year
-29022.0%
YoY Change
-1337900 bps
Net Margin
Current Quarter
-42401.0%
Prior Year
-20216.0%
YoY Change
-2218500 bps

Margin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.

MANAGEMENT COMMENTARY

The past year marked a period of significant execution and progress for Janux as we continued to translate the promise of our tumor-activated platform into meaningful clinical and strategic advances.

— Janux Therapeutics, Inc., Q4 FY2025 2025 Earnings Call

Recent JANX007 clinical results demonstrate clinical activity and a consistent and predictable safety profile in mCRPC and support continued advancement in taxane-naïve patients as well as other expansion cohorts.

— Janux Therapeutics, Inc., Q4 FY2025 2025 Earnings Call

In early 2026, we announced a collaboration with Bristol Myers Squibb that provides near-term capital and further validates the potential of our platform.

— Janux Therapeutics, Inc., Q4 FY2025 2025 Earnings Call

Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.